Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16 Sep - Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Source: Bse
Rossari Biotech Limited (ROSSARI)
Small CapPharma stocks · Small cap · NSE
Rossari Biotech Limited operates in Textile Chemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result18 Jul, 10:16 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
62BullishSMA20 -7.6% / mo · MACD + · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 38
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
ROSSARID candles · FIT view-15.3%Latest close ₹437.50 on 2026-10-19
Bar
-3.3%
RSI
48
MACD hist
4.33
52W pos
22%
2026-10-19O ₹452.50H ₹458.00L ₹431.35C ₹437.50Vol 1.4L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ROSSARINifty PharmaNifty 500
- ROSSARI
- -15.6%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -10.1 pp
Chart stats
19 Oct 2026- From 52W high
- -36.6%
- 52W range position
- 20%
- ATR (14)
- 3.9%
- Volume vs 20D
- 2.04x
- Avg traded value
- ₹3.2 Cr
- 20D price channel
- ₹404.1 - ₹474.2
₹690.3
₹375 - ₹690.3
₹16.9
Latest completed session
20-session average
35.0% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE55
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average32
Revenue +28.1% · PAT +2.9% YoY
Technical
Bullish62
Price trend and sector-relative-strength timing.
Valuation
Legacy model+63.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence73
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 32/100margin compression · Rev +28% YoY · PAT +3% YoY
Filed 18 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹697 Cr | +28.1% | +1.8% |
| EBITDA | ₹81 Cr | +19.1% | +5.2% |
| Operating margin | 12.0% | +0 bps | +100 bps |
| PAT | ₹35 Cr | +2.9% | -23.9% |
| PAT margin | 5.0% | -123 bps | -170 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 15.80
- P/B
- 1.79
- EV/EBITDA
- 7.31
- Market Cap
- 2385.00Cr
Profitability
- ROE
- 10.80%
- ROCE
- 13.30%
- ROA
- 6.64%
- Dividend Y
- 0.12%
Growth (CAGR)
- Revenue 5Y
- 28.00%
- EPS 5Y
- 11.00%
- Revenue 3Y
- 13.00%
- EPS 3Y
- 8.00%
Balance Sheet
- Debt/Equity
- 0.33
- Interest Coverage
- 8.79×
- Altman Z
- 4.10
- Book Value
- 241.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- 65.00 Cr
- EPS TTM
- 27.22
Shareholding
- Promoter Hold
- 68.14%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 18%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 2,661+11.1% vs prev
Net Profit
₹ CrLatest: 149+9.6% vs prev
Return on Equity
%Latest: 11.2-2.6% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 48. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~8.2% over last month) — short-term momentum negative.
- RSI(14) at 48 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 34% off 52W high · 17% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
24
RS percentile
Stage 4 Downtrend
1M return
-0.1%
3M return
-15.6%
6M return
-14.7%
1Y return
-32.7%
RS 1D
-2
RS 20D
0
Sector rank
#1
Industry rank
-
Stage evidence
- Price is 10.0% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.0%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 71.51-2.79%
RS vs Nifty 50072
Valuation & peers
U-Score 55 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 55 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation20/30
Growth13/25
Quality2/20
Balance Sheet12/15
Cash Flow2/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
55
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
55/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 63.5%.
- Balance sheet contributes 12/15 to the score.
Main drags
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Cash flow is weaker at 2/10; verify the latest quarterly trend.
- Growth is weaker at 13/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
15.8
PB
1.8
EV/EBITDA
7.3
ROE
10.8%
ROCE
13.3%
FCF Yield
—
Debt/Equity
0.3
MoS
+63.5%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
55
Previous: 55
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+63.5%
Previous: +63.5%
Score history
12 stored score snapshots. Latest stored move: +1 points.
20 Oct 2026
v4.3-runtime-valuation
55
54
54
54
54
54
55
55
53
53
54
55
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹384.19
-13.9% MoS
Growth-justified P/E
44.0
Growth-justified Value
₹1,197.14
+63.5% MoS
PEG
1.61
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
TATVA
Small
Tatva Chintan Pharma Chem Limited
Specialty Chemicals
match 118
19
70.8
5.5%
-1191%
OVERVALUED
JGCHEM
Small
J.G.Chemicals Limited
Specialty Chemicals
match 117
43
31.8
13.2%
+19%
WATCHLIST
PAR
Small
Par Drugs And Chemicals Limited
Specialty Chemicals
match 116
43
10.5
9.9%
-15%
WATCHLIST
BODALCHEM
Small
Bodal Chemicals Limited
Specialty Chemicals
match 115
26
33.0
2.0%
-770%
OVERVALUED
SHK
Small
S H Kelkar and Company Limited
Specialty Chemicals
match 114
31
40.3
3.7%
-707%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Rossari Biotech Limited operates in Textile Chemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
73Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 72nd percentile of the scored universe and 63rd percentile within Pharma. Main check: financial discipline is weak at 50/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
101 docs text-extracted · 37 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
72nd percentile
overall median 67 · Pharma: 63rd pctile, median 70 · Small: 75th pctile, median 66
Evidence depth
Financial-only
101 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
55
watch · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
50
watch · capital discipline
Results
95
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 68.1%.
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸4/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸ROCE trend is -2.4%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Rossari Biotech Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Aug - Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Source: Bse
Investor presentationJul 2026
Jul 2026 · PPT
Source: Bse
Concall transcriptJul 2026
Jul 2026 · Transcript
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Jun - Newspaper Publication of Notice of 17th Annual General Meeting of the Company and details relating to E-voting facility
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 Jun - Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.